• 1
    American Cancer Society. Cancer facts and figures 2004. Atlanta: American Cancer Society, 2004.
  • 2
    Phillips KA, Bernhard J. Adjuvant breast cancer treatment and cognitive function: current knowledge and research directions. J Natl Cancer Inst. 2003; 95: 190197.
  • 3
    Morse R, Rodgers J, Verrill M, Kendell K. Neuropsychological functioning following systemic treatment in women treated for breast cancer: a review. Eur J Cancer. 2003; 39: 22882297.
  • 4
    Wieneke MH, Dienst ER. Neuropsychological assessment of cognitive functioning following chemotherapy for breast cancer. Psychooncology. 1995; 4: 6166.
  • 5
    Van Dam FS, Schagen SB, Muller MJ, et al. Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard dose chemotherapy. J Natl Cancer Inst. 1998; 90: 210218.
  • 6
    Schagen SB, van Dam FS, Muller MJ, Boogerd W, Lindeboom J, Bruning PF. Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma. Cancer. 1999; 85: 640650.
  • 7
    Schagen SB, Muller MJ, Boogerd W, et al. Late effects of adjuvant chemotherapy on cognitive function: a follow-up study in breast cancer patients. Ann Oncol. 2002; 13: 13871397.
  • 8
    Brezden CB, Phillips K, Abdolell M, Bunston T, Tannock IF. Cognitive function in breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol. 2000; 18: 26952701.
  • 9
    Ahles TA, Saykin AJ, Furstenberg CT, et al. Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J Clin Oncol. 2002; 20: 485493.
  • 10
    Servaes P, Verhagen CA, Bleijenberg G. Relations between fatigue, neuropsychological functioning, and physical activity after treatment for breast carcinoma: daily self-report and objective behavior. Cancer. 2002; 95: 20172026.
  • 11
    Wefel JS, Lenzi R, Theriault RL, Davis RN, Meyers CA. The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma. Cancer. 2004; 100: 22922299
  • 12
    Andrykowski MA, Schmidt JM, Salsman JE, Beachman AO, Jacobsen PB. Use of a case definition approach to identify prevalence of cancer-related fatigue in women undergoing adjuvant therapy for early stage breast cancer. J Clin Oncol. 2005; 23: 66136622.
  • 13
    Donovan KA, Jacobsen PB, Andrykowski MA, et al. Course of fatigue in women receiving chemotherapy and/or radiotherapy for early stage breast cancer. J Pain Symptom Manage. 2004; 28: 373380.
  • 14
    Andrykowski MA, Schmitt FA, Gregg ME, Brady MJ, Lamb DG, Henslee-Downey PJ. Neuropsychologic impairment in adult bone marrow transplant candidates. Cancer. 1992; 70: 22882297.
  • 15
    Schmitt FA, Bigley JW, McKinnis R, et al. Neuropsychological outcome of azidothymidine (AZT) in the treatment of AIDS and AIDS-related complex: a double-blind, placebo-controlled trial. N Engl J Med. 1988; 319: 15731578.
  • 16
    Schmitt FA, Wetherby M, Stern Y. Neuropsychological aspects of HIV infection. In: LevyR, BergerJ, editors. AIDS and the nervous system. New York: Raven Press, 1996.
  • 17
    Nelson HE. The National Adult Reading Test (NART): test manual. Windsor, Berks, UK: NFER-Nelson, 1982.
  • 18
    Crawford JR, Parker DM, Steward LE, et al. Prediction of WAIS IQ with the National Adult Reading Test: cross-validation and extension. Br J Clin Psychol. 1989; 28: 267273.
  • 19
    Delis DC, Kramer JH, Kaplan E, et al. California Verbal Learning Test: adult version. San Antonio, TX: Psychological Corporation, 1987.
  • 20
    Wechsler D. Wechsler Memory Scale-III manual. San Antonio, TX: Psychological Corporation, 1997.
  • 21
    Wechsler D. WAIS-III administration and scoring manual. San Antonio, TX: Psychological Corporation, 1997.
  • 22
    Reitan RM, Wolfson D. The Halstead-Reitan Neuropsychological Test Battery: theory and clinical interpretation. Tucson, AZ: Neuropsychology Press, 1993.
  • 23
    Benton AL, Hamsher K. Multilingual aphasia examination. Iowa City, IA: AJA Associates, 1989.
  • 24
    Seidenberg M, Haltiner A, Taylor MA, et al. Development and validation of a multiple ability self-report questionnaire. J Clin Exp Neuropsychol. 1994; 16: 93104.
  • 25
    Heaton RK, Grant I, Matthews CG. Comprehensive norms for an expanded Halstead-Reitan Battery: demographic correction, research findings, and clinical applications. Odessa, FL: Psychological Assessment Resources, 1991.
  • 26
    Cohen J. Statistical power analysis for the behavioral sciences, 2nd ed. Hillsdale, NJ: Lawrence Erlbaum, 1988.
  • 27
    Hann DM, Jacobsen PB, Azzarello LM, et al. Measurement of fatigue in cancer patients: development and validation of the Fatigue Symptom Inventory. Qual Life Res. 1994; 7: 301310.
  • 28
    Radloff LS. The CES-D scale: a self-report depression scale for research in the general population. Appl Psych Meas. 1977; 1: 385401.
  • 29
    Cull A, Hay C, Love SB, Mackie M, Smets E, Stewart M. What do cancer patients mean when they complain of concentration and memory problems? Br J Cancer. 1996; 74: 16741679.
  • 30
    Tannock IF, Ahles TA, Ganz PA, van Dam FS. Cognitive impairment associated with chemotherapy for cancer: report of a workshop. J Clin Oncol. 2004; 22: 22332239.
  • 31
    Bennett DA, Wilson RS, Schneider J, et al. Apolipoprotein E epsilon4 allele, AD pathology, and the clinical expression of Alzheimer's disease. Neurology. 2003; 60: 246252.
  • 32
    Small BJ, Rosnick C, Fratiglioni L, Backman L. Apolipoprotein E and cognitive performance: a meta-analysis. Psychol Aging. 2004; 19: 592600.
  • 33
    Friedman G, Froom P, Sazbon L, et al. Apolipoprotein E-ϵ4 genotype predicts a poor outcome in survivors of traumatic brain injury. Neurology. 1999; 52: 244248.
  • 34
    Ahles TA, Saykin AJ, Noll WW, et al. The relationship of APOE genotype to neuropsychological performance in long-term cancer survivors treated with standard dose chemotherapy. Psychooncology. 2003; 12: 612619.
  • 35
    Bender CM, Paraska KK, Sereika SM, Ryan CM, Berga SL. Cognitive function and reproductive hormones in adjuvant therapy for breast cancer: a critical review. J Pain Symptom Manage. 2001; 21: 407424.
  • 36
    Rugo HS, Ahles T. The impact of adjuvant therapy for breast cancer on cognitive function: current evidence and directions for research. Semin Oncol. 2003; 30: 749762.